Ivan D. Horak spends much of his time researching Immunology, Molecular biology, Cancer research, Interleukin 2 and Immune system. He integrates many fields, such as Immunology and Gene mutation, in his works. His Cancer research research is multidisciplinary, incorporating perspectives in Haematopoiesis and Transcription factor.
His Interleukin 2 research includes themes of T cell, Lymphocytic choriomeningitis, B cell, Vesicular stomatitis virus and Autoimmunity. His Immune system research includes elements of Cytotoxic T cell, CD40, Antibody and Antigen. The study incorporates disciplines such as Colitis, Inflammatory bowel disease and Ulcerative colitis in addition to Antigen.
His scientific interests lie mostly in Molecular biology, Cancer research, Immunology, Antibody and In vivo. As a part of the same scientific family, Ivan D. Horak mostly works in the field of Molecular biology, focusing on Transfection and, on occasion, Oligonucleotide, Locked nucleic acid and Cell biology. His research on Cancer research also deals with topics like
His study in Immune system, Interleukin 2, Immunoglobulin G, Cytokine and B cell is done as part of Immunology. His research in Immune system is mostly focused on T cell. His research investigates the connection between Antibody and topics such as Cell culture that intersect with problems in Recombinant DNA.
The scientist’s investigation covers issues in Cancer research, Molecular biology, In vivo, Internal medicine and Pharmacology. Ivan D. Horak incorporates Cancer research and Syngeneic mouse in his research. His Molecular biology study integrates concerns from other disciplines, such as Cancer, Prostate, Transfection and Locked nucleic acid, Oligonucleotide.
He has included themes like Protein kinase B and Cell biology in his Transfection study. His work in Oncology addresses issues such as Immunity, which are connected to fields such as Antibody. His Antibody research focuses on subjects like Longevity, which are linked to Cell culture.
Ivan D. Horak mainly investigates Pharmacology, Cancer research, Lapatinib, PI3K/AKT/mTOR pathway and Camptothecin. Ivan D. Horak has researched Pharmacology in several fields, including Downregulation and upregulation, Western blot, Signal transduction and Transcription factor. In his works, Ivan D. Horak performs multidisciplinary study on Cancer research and Vincristine.
In his papers, Ivan D. Horak integrates diverse fields, such as Lapatinib, Gefitinib, Cell growth, Tyrosine kinase, Akt/PKB signaling pathway and Kinase activity. Ivan D. Horak interconnects Carcinogenesis, Protein kinase B, Growth inhibition and Proto-oncogene tyrosine-protein kinase Src in the investigation of issues within PI3K/AKT/mTOR pathway. His Camptothecin research integrates issues from Angiogenesis, Chorioallantoic membrane, Matrigel, Glioma and MMP2.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.
Benjamin Sadlack;Hartmut Merz;Hubert Schorle;Anneliese Schimpl.
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.
Hubert Schorle;Thomas Holtschke;Thomas Hünig;Anneliese Schimpl.
Immunodeficiency and Chronic Myelogenous Leukemia-like Syndrome in Mice with a Targeted Mutation of the ICSBP Gene
Thomas Holtschke;Jürgen Löhler;Yuka Kanno;Thomas Fehr.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End.
Immune responses in interleukin-2-deficient mice
Thomas M. Kundig;Hubert Schorle;Martin F. Bachmann;Hans Hengartner.
Generalized autoimmune disease in interleukin‐2‐deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells
Benjamin Sadlack;Jürgen Löhler;Hubert Schorle;Gabriele Klebb.
European Journal of Immunology (1995)
Sialylation is essential for early development in mice
Martina Schwarzkopf;Klaus-Peter Knobeloch;Elvira Rohde;Stephan Hinderlich.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma
Rhona Stein;Zhengxing Qu;Susan Chen;Adriane Rosario.
Clinical Cancer Research (2004)
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Susan J. Knox;Michael L. Goris;Margaret Tempero;Paul L. Weiden.
Clinical Cancer Research (2000)
T-lymphocyte interleukin 2-dependent tyrosine protein kinase signal transduction involves the activation of p56lck.
Ivan D. Horak;Ronald E. Gress;Phillip J. Lucas;Eva M. Horak.
Proceedings of the National Academy of Sciences of the United States of America (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: